Plus Therapeutics

03/09/2026

International Women’s Day was yesterday and March is Women’s History Month.

Our team honors the women advancing science, medicine, and innovation to push the boundaries of cancer treatment to bring hope to patients and families worldwide.

03/06/2026

Happy !

From research to development and beyond, we are proud to celebrate the lab staff, commercial team, and industry experts behind our mission of addressing some of the toughest challenges in central nervous system cancers.

We are grateful for your hard work, your collaboration, and the positive impact you make on our team and community.

Thank you for everything you do!

Pictured: Some of our onsite staff in Houston

03/05/2026

ongoing ReSPECT-LM dose-optimization for REYOBIQ™ in patients with (LM) aims to expand treatment options for the challenging CNS complication.

is also harnessing REYOBIQ™ for recurrent ) in a trial for cancer patients with a glioma that has come back after standard treatment options like surgery, radiation, or chemotherapy.

Learn more about both of these ongoing here: www.respect-trials.com

02/28/2026

Today is , an annual moment dedicated to raising awareness to advance efforts for the 300+ million people with across the globe.

is proud of the tests our wholly-owned subsidiary, CNSide Diagnostics, is developing to improve the ability to detect and treat a rare complication of cancer, (LM), much earlier.

Learn more about our efforts to combat LM, including ongoing RESPECT-LM : www.respect-trials.com/lm

Leptomeningeal Cancer Foundation

02/25/2026

announces the American Medical Association’s CPT® Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used in the administration of for recurrent and pediatric .

Full press release here: bit.ly/4saQomG

02/18/2026

February is . In 2025, over 2 million people were diagnosed with cancer and over 600 thousand died from this devastating disease in the US, despite 40% of these cases being preventable (American Association for Cancer Research (AACR)).

CNSide Diagnostics’ Cerebrospinal Fluid Assay Platform was developed for patients with suspected to support the prompt diagnosis and treatment initiation essential to improving the chances of controlling the disease, managing symptoms, and extending survival.

Learn more about our game changing diagnostic technology: cnside-dx.com

02/11/2026

On International Day of Women and Girls in Science, we wanted to highlight a few members of our exceptional CNSide Diagnostics' on-site lab team!

We’re proud to celebrate the game changing innovative women working across the and teams, as well as across the world, who drive forward our efforts to develop lasting solutions for treating rare and difficult-to-treat cancers for patients.

02/11/2026

CNSide Diagnostics Medical Science Liason, Kelly Kreitzburg Ondrasek, PhD, attended the National Comprehensive Cancer Network's event to share the latest updates and coming milestones of the Cerebrospinal Fluid Assay Platform for patients with suspected .

Thank you to all who stopped by our booth! Learn more here: cnside-dx.com

02/09/2026

Pharma's Almanac recently asked several key biopharma leaders: What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?

' President and CEO, Marc Hedrick, MD, believes that the future of biopharma will be driven by advances in precision medicine, particularly within the metastatic CNS cancers such as , as researchers gain a deeper understanding of metastatic cancer biology.

Check out Dr. Hedrick’s full response here: https://bit.ly/4tpHEdz

CNSide Diagnostics

02/03/2026

As we move into 2026, and CNSide Diagnostics are progressing forward with a shared focus on improving care for CNS cancer patients.

Coming off a strong 2025, our team is looking forward to advancing each of these key milestones, which reflect a continued commitment to innovation, access, and impact in the fight against cancer.

Learn more via our newest corporate presentation: bit.ly/3ZfdJqN

01/29/2026

In a recent interview with Karen Jagoda of Empowered Patient Radio, Marc Hedrick, President & CEO of , provides a comprehensive overview of 's work to advance diagnostics, targeted , and data for central nervous system (CNS) cancers, with the goal of improving patient outcomes and addressing significant unmet needs in neuro-oncology.

Listen to their discussion here: https://bit.ly/3NE4uxY

CNSide Diagnostics

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic....

01/26/2026

CNSide Diagnostics has several open positions based out of our new Houston, TX facility.

View all our open positions here: https://hubs.la/Q040lXzP0
Learn more about CNSide: https://hubs.la/Q040lTxM0